Phase 2 clinical study for patients with dcSSc or PAH
Phase 2 clinical study for patients with diffuse cutaneous systemic sclerosis (dcSSc) or patients with pulmonary arterial hypertension (PAH)
The American company, Cumberland Pharmaceuticals, is conducting a phase 2 clinical study evaluating the safety and effectiveness of a new oral drug product in patients with diffuse cutaneous systemic sclerosis (dcSSc) or patients with pulmonary arterial hypertension (PAH) associated with their scleroderma. The study is open at 6 Scleroderma Centers of Excellence and opening at more centers with active Scleroderma Research programs.
General study information can be found at the study’s NCT website (NCT02682511). Eligible subjects will be reimbursed for their time and travel. If you are interested in learning more, please contact us at 615-627-4121 or email@example.com
At the moment the study is targeted Australia, Canada, South Africa, India and U.S.
news & events
PRESS RELEASE: European associations align in the battle against systemic sclerosis for World Scleroderma Day 2019
We are happy to share with you the latest newsletter from FESCA.
The juvenile scleroderma inceptions project has the aim to learn more about juvenile Systemic Sclerosis.